Michael P. Hengartner

Michael Pascal Hengartner is an academic psychologist at the Zurich University of Applied Sciences who has published on the subject of antidepressants and in other areas.[1][2] In 2022, he published a book called Evidence-Biased Antidepressant Prescription: Overmedicalisation, Flawed Research, and Conflicts of Interest.[2] He has also published with other notable researchers such as Joanna Moncrieff[3][4] and Irving Kirsch.[5][6]

Michael Pascal Hengartner

MSc, PhD
NationalitySwiss
EducationMaster of Science (MSc): clinical psychology, psychopathology, and criminology (2009); Doctor of Philosophy (PhD): psychology (2013)[1]
Occupation(s)Psychologist; Professor; Medical researcher
Years active2010–present
Medical career
ProfessionProfessor; Psychologist; Researcher
InstitutionsSection for Clinical Psychology and Health Psychology, ZHAW School of Applied Psychology
ResearchPsychiatry; Psychology
Notable worksEvidence-biased Antidepressant Prescription Overmedicalisation, Flawed Research, and Conflicts of Interest (Hengartner, 2022)

Selected publications

Books

  • Hengartner, Michael P. (2022). Evidence-Biased Antidepressant Prescription: Overmedicalisation, Flawed Research, and Conflicts of Interest. Springer International Publishing. doi:10.1007/978-3-030-82587-4.

Papers

References

  1. "Dr. Michael Pascal Hengartner". ZHAW Zurich University of Applied Sciences. 14 July 2021. Retrieved 23 September 2022.
  2. Hengartner, Michael P. (2022). Evidence-Biased Antidepressant Prescription: Overmedicalisation, Flawed Research, and Conflicts of Interest. Springer International Publishing. doi:10.1007/978-3-030-82587-4.
  3. Moncrieff J, Cooper RE, Stockmann T, Amendola S, Hengartner MP, Horowitz MA (July 2022). "The serotonin theory of depression: a systematic umbrella review of the evidence". Mol Psychiatry. doi:10.1038/s41380-022-01661-0. PMID 35854107.
  4. Hengartner MP, Moncrieff J (2018). "Inconclusive Evidence in Support of the Dopamine Hypothesis of Psychosis: Why Neurobiological Research Must Consider Medication Use, Adjust for Important Confounders, Choose Stringent Comparators, and Use Larger Samples". Front Psychiatry. 9: 174. doi:10.3389/fpsyt.2018.00174. PMC 5938402. PMID 29765340.
  5. Juul S, Siddiqui F, Barbateskovic M, Jørgensen CK, Hengartner MP, Kirsch I, Gluud C, Jakobsen JC (May 2021). "Beneficial and harmful effects of antidepressants versus placebo, 'active placebo', or no intervention for adults with major depressive disorder: a protocol for a systematic review of published and unpublished data with meta-analyses and trial sequential analyses". Syst Rev. 10 (1): 154. doi:10.1186/s13643-021-01705-6. PMC 8152051. PMID 34034811.
  6. Jørgensen CK, Juul S, Siddiqui F, Barbateskovic M, Munkholm K, Hengartner MP, Kirsch I, Gluud C, Jakobsen JC (August 2021). "Tricyclic antidepressants versus 'active placebo', placebo or no intervention for adults with major depressive disorder: a protocol for a systematic review with meta-analysis and Trial Sequential Analysis". Syst Rev. 10 (1): 227. doi:10.1186/s13643-021-01789-0. PMC 8361619. PMID 34389045.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.